JP2013528650A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528650A5
JP2013528650A5 JP2013515459A JP2013515459A JP2013528650A5 JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5 JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5
Authority
JP
Japan
Prior art keywords
ylthio
bromo
triazol
acetic acid
cyclopropylnaphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515459A
Other languages
English (en)
Japanese (ja)
Other versions
JP5964821B2 (ja
JP2013528650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040398 external-priority patent/WO2011159732A1/en
Publication of JP2013528650A publication Critical patent/JP2013528650A/ja
Publication of JP2013528650A5 publication Critical patent/JP2013528650A5/ja
Application granted granted Critical
Publication of JP5964821B2 publication Critical patent/JP5964821B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515459A 2010-06-15 2011-06-14 痛風と高尿酸血症の処置 Expired - Fee Related JP5964821B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US61/355,004 2010-06-15
US41144910P 2010-11-08 2010-11-08
US61/411,449 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US61/430,522 2011-01-06
US201161489420P 2011-05-24 2011-05-24
US61/489,420 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (3)

Publication Number Publication Date
JP2013528650A JP2013528650A (ja) 2013-07-11
JP2013528650A5 true JP2013528650A5 (enExample) 2014-06-05
JP5964821B2 JP5964821B2 (ja) 2016-08-03

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515459A Expired - Fee Related JP5964821B2 (ja) 2010-06-15 2011-06-14 痛風と高尿酸血症の処置

Country Status (19)

Country Link
US (3) US9216179B2 (enExample)
EP (1) EP2582683B1 (enExample)
JP (1) JP5964821B2 (enExample)
CA (1) CA2802407C (enExample)
CY (1) CY1120473T1 (enExample)
DK (1) DK2582683T3 (enExample)
ES (1) ES2670700T3 (enExample)
HR (1) HRP20180780T1 (enExample)
HU (1) HUE038265T2 (enExample)
LT (1) LT2582683T (enExample)
NO (1) NO2019008I1 (enExample)
PL (1) PL2582683T3 (enExample)
PT (1) PT2582683T (enExample)
RS (1) RS57275B1 (enExample)
SI (1) SI2582683T1 (enExample)
SM (1) SMT201800266T1 (enExample)
TR (1) TR201806828T4 (enExample)
WO (1) WO2011159732A1 (enExample)
ZA (1) ZA201300055B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
ES2704233T3 (es) * 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
MA43402A (fr) * 2015-12-08 2018-10-17 Ardea Biosciences Inc Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
US12152347B2 (en) 2018-10-26 2024-11-26 The Procter & Gamble Company Sanitary tissue product rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法
US12679581B2 (en) 2022-08-31 2026-07-14 The Procter & Gamble Company Sanitary tissue product packages and arrays comprising shoulder area ratio(s)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063788A1 (ja) 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ME01512B (me) 2004-08-25 2014-04-20 Ardea Biosciences Inc S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze
RU2009131454A (ru) 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
AU2011203708B2 (en) 2010-01-08 2013-08-01 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and uses thereof
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
CN103249417A (zh) * 2010-10-15 2013-08-14 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
MY172534A (en) * 2010-12-30 2019-11-29 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
JP5964952B2 (ja) 2011-05-24 2016-08-03 アルデア バイオサイエンシーズ インク. 高血圧症と高尿酸血症

Similar Documents

Publication Publication Date Title
JP2013528655A5 (enExample)
Grassi et al. Clinical features of gout
JP5964821B2 (ja) 痛風と高尿酸血症の処置
JP2012184234A5 (enExample)
JP2014532726A5 (enExample)
JP2009533356A5 (enExample)
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
Pascual et al. Febuxostat
JP2013087119A5 (enExample)
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
CA2862602A1 (en) Therapeutic agent for diabetes
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP2018536638A5 (enExample)
EA028495B1 (ru) Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина
JP2004534760A (ja) 腎線維症の治療
EP3834828B1 (en) Composition comprising a thiamine derivative for use in the prevention or treatment of vascular or cardiac valve calcification
CN118178378A (zh) 10-羟基-2-癸烯酸在防治高尿酸血症中的用途
Ahn et al. SAT0356 the therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout
RU2007133712A (ru) Способы улучшения распределения лекарственных средств
Wipfler-Freißmuth et al. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report
KR101647348B1 (ko) Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
CN108420823A (zh) 一种选择性抑制痛风结石和尿酸肾结石晶体嘌呤衍生物的应用
JP6028983B2 (ja) ビダラビンによる心房細動治療
JP2019504085A5 (enExample)
Szczepański et al. Is Urate-lowering therapy a prevention of first gout episode?